drugset / Trial / NCT02494206
Immunotherapy for the Treatment of Breast Cancer Related Upper Extremity Lymphedema (BCRL)
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the efficacy of QBX258, a compound developed by Novartis Corporation composed of two antibodies, in reducing arm volume excess in women with stage I-II breast cancer related lymphedema.
Timeline
- Start
- 2015-07
- Primary completion
- 2018-05
- Completion
- 2018-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | QAX576 | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | VAK694 | Unknown | 3 mg/kg | Intravenous |